- Home
- NEWT vs AVIR Comparison
NEWT vs AVIR Comparison
Compare NEWT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWT | AVIR |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.5M | 450.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NEWT | AVIR |
|---|---|---|
| Price | $10.46 | $5.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.00 | $8.00 |
| AVG Volume (30 Days) | 183.9K | ★ 578.2K |
| Earning Date | 05-05-2026 | 03-05-2026 |
| Dividend Yield | ★ 6.87% | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.45 | N/A |
| P/E Ratio | $5.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.12 | $2.46 |
| 52 Week High | $14.91 | $6.45 |
Technical Indicators
Market Signals| Indicator | NEWT | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 26.39 | 44.56 |
| Support Level | $10.28 | $3.33 |
| Resistance Level | $12.41 | $6.45 |
| Average True Range (ATR) | 0.37 | 0.29 |
| MACD | -0.09 | -0.15 |
| Stochastic Oscillator | 0.50 | 5.36 |
Price Performance
Historical ComparisonAbout NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.